How PBI/Gordon Companies leveraged our Sirolimus API Market report
VM Intelligence · Sample preview · Healthcare and Pharmaceuticals · Forecast 2027–2033
Exosome Detection Service Market
- By Detection Technology: Nanoparticle Tracking Analysis (NTA), Flow Cytometry, Enzyme-Linked Immunosorbent Assay (ELISA), Western Blotting, Surface Plasmon Resonance (SPR), Microfluidics-based Detection
- By Exosome Source: Blood Plasma, Urine, Saliva, Cerebrospinal Fluid, Cell Culture Media, Breast Milk
- By Application: Cancer Diagnostics, Neurological Disorder Research, Cardiovascular Disease Monitoring, Drug Delivery Research, Regenerative Medicine
- By Service Provider Type: Contract Research Organizations (CROs), Academic and Research Institutions, Biotechnology Companies, Clinical Diagnostic Laboratories
Key Highlights
A snapshot of what the full report proves- 01 Market size - $X,XXX.XM global market in 2025 - the verified base-year revenue. Executive Summary →
- 02 Forecast - Full 2033 market projection modelled inside - unlock the forecast value to see where the market lands. Market Outlook →
- 03 Growth - Year-by-year CAGR across 2027–2033 - unlock the growth rate and the full model. Market Outlook →
- 04 Leading segment - Nanoparticle Tracking Analysis (NTA) leads By Detection Technology at XX% share. Market, by Service Type →
- 05 Global coverage - Sized across 5 regions and 20 countries, each broken out by segment. Market, by Geography →
- 06 Competitive landscape - 15 companies profiled with SWOT, benchmarking and market-share analysis. Company Profiles →
Inside the Report
11 chapters · 284 pages- 01 Introduction Definition, segmentation & scope p.12 →
- 02 Research Methodology How the numbers were built p.20 →
- 03 Executive Summary The market in one chapter p.34 →
- 04 Market Outlook Drivers, restraints, trends p.63 →
- 10 Competitive Landscape 5 sections p.170 →
- 11 Company Profiles 15 players: SWOT & benchmarking p.178 →
Full report · locked preview
Everything inside the Exosome Detection Service Market report
A complete, evidence-based study - 11 chapters and 119 sections covering market size, segmentation across 4 axes, regional analysis and 15 company profiles, forecast to 2033.
Segmentation covered
Detection Technology 6
Exosome Source 6
Application 5
Service Provider Type 4
Companies profiled
NanoView Biosciences
Exosome Diagnostics (a Bio-Techne brand)
HansaBioMed Life Sciences
System Biosciences (SBI)
Thermo Fisher Scientific
Miltenyi Biotec
SBI (System Biosciences)
Bio-Techne
QIAGEN
Cytodiagnostics
Fuji Film Wako
Norgen Biotek
+3 more
Verified · Analyst-reviewed · No payment to preview
Trusted & certified by
★★★★★ Excellent
★★★★★ Excellent
15 players profiled - tiered by revenue contribution, footprint and R&D capability.
ACE Matrix · p.153 →NanoView Biosciences
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.155 →Exosome Diagnostics (a Bio-Techne brand)
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.160 →HansaBioMed Life Sciences
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.166 →System Biosciences (SBI)
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.173 →Thermo Fisher Scientific
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.178 →Miltenyi Biotec
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.184 →SBI (System Biosciences)
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking · Segment breakdown
Full profile · p.191 →Bio-Techne
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.196 →QIAGEN
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.202 →Cytodiagnostics
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking · Segment breakdown
Full profile · p.209 →Fuji Film Wako
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.214 →Norgen Biotek
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.220 →ExoCoBio
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.227 →Evox Therapeutics
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.232 →Capricor Therapeutics
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.238 →Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Global · 2025–2033
$4,144M by 2033 · 3.4% CAGR
Market estimates & forecast (USD Million)
Fig. 15 · p.34 →Segment mix, 2033 (% share)
Fig. 16 · p.35 →- Nanoparticle Tracking Analysis (NTA)34.5
- Flow Cytometry8.5
- Enzyme-Linked Immunosorbent Assay (ELISA)18.6
- Western Blotting17.0
- Surface Plasmon Resonance (SPR)8.8
- Microfluidics-based Detection12.7
Regions, 2025 → 2033 (USD Mn)
§6.1 · p.75 →North America$1,051M → $1,313M · 2.8%
Europe$732.2M → $1,072M · 4.9%
Asia Pacific$668.5M → $908.2M · 3.9%
Latin America$413.8M → $535.6M · 3.3%
Middle East and Africa$318.3M → $444.0M · 4.2%
Top countries, 2033 (USD Mn)
§6.2 · p.78 →Year-over-year growth (%)
§3.12 · p.44 →3.302026
3.312027
3.332028
3.332029
3.352030
3.362031
3.362032
3.382033
CAGR by region (%)
Fig. 22 · p.71 →Market share by company, 2033 (%)
Fig. 41 · p.152 →- NanoView Biosciences22.8
- Exosome Diagnostics (a Bio-Techne brand)12.2
- HansaBioMed Life Sciences11.9
- System Biosciences (SBI)8.1
- Thermo Fisher Scientific11.4
- Miltenyi Biotec5.6
- Others28.0
Segment contribution to growth (%)
Fig. 18 · p.39 →Detection Technology20.7%
Exosome Source18.2%
Application32.9%
Service Provider Type28.2%
Competitive positioning (ACE matrix)
Fig. 40 · p.153 →Adoption & penetration (% of addressable)
Fig. 12 · p.31 →Revenue by application (USD Mn)
§5.3 · p.62 →Demand by end-use (USD Mn)
§5.4 · p.66 →Average selling price trend (index, 2025=100)
Fig. 27 · p.58 →Top companies by revenue, 2033 (USD Mn)
Fig. 42 · p.155 →Revenue by region, 2033 (%)
Fig. 20 · p.70 →- North America30.7
- Europe25.1
- Asia Pacific21.3
- Latin America12.5
- Middle East and Africa10.4
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
8 players benchmarked across 6 dimensions — scored 0–100 from share, portfolio, reach, innovation, financials and installed base. Methodology · §8.1 · p.160 →
Competitive scorecard (score 0–100)
Table 31 · p.161 →| Company | Market share | Product portfolio | Geographic reach | Innovation & R&D | Financial strength | Customer base | Composite |
|---|---|---|---|---|---|---|---|
| NanoView Biosciences | 83 | 80 | 74 | 81 | 97 | 94 | 85 |
| Exosome Diagnostics (a Bio-Techne brand) | 83 | 73 | 68 | 78 | 80 | 70 | 75 |
| HansaBioMed Life Sciences | 85 | 74 | 72 | 88 | 87 | 80 | 81 |
| System Biosciences (SBI) | 82 | 75 | 82 | 73 | 70 | 64 | 74 |
| Thermo Fisher Scientific | 51 | 69 | 58 | 77 | 72 | 53 | 63 |
| Miltenyi Biotec | 50 | 48 | 66 | 54 | 47 | 71 | 56 |
| SBI (System Biosciences) | 59 | 49 | 57 | 46 | 42 | 55 | 51 |
| Bio-Techne | 45 | 60 | 52 | 47 | 54 | 48 | 51 |
Vendor positioning (presence × innovation)
Fig. 43 · p.163 →Strengths profile (top 3 players)
Fig. 44 · p.165 →- NanoView Biosciences
- Exosome Diagnostics (a Bio-Techne brand)
- HansaBioMed Life Sciences
Capability coverage
§8.3 · p.168 →| Company | Global delivery | R&D depth | Digital platform | Sustainability | After-sales | Custom solutions |
|---|---|---|---|---|---|---|
| NanoView Biosciences | ✓ | ◐ | ◐ | ◐ | ✓ | ✓ |
| Exosome Diagnostics (a Bio-Techne brand) | ◐ | ◐ | − | ◐ | ◐ | ◐ |
| HansaBioMed Life Sciences | ◐ | ◐ | ◐ | ◐ | ✓ | ◐ |
| System Biosciences (SBI) | ◐ | ◐ | ◐ | ✓ | ◐ | ✓ |
| Thermo Fisher Scientific | ◐ | ◐ | − | ✓ | − | − |
| Miltenyi Biotec | − | − | ◐ | − | − | ◐ |
| SBI (System Biosciences) | ◐ | − | ◐ | ◐ | − | − |
| Bio-Techne | − | ◐ | ◐ | − | ◐ | ◐ |
✓ Full ◐ Partial − Limited
Overall competitive index (composite, ranked)
Fig. 45 · p.170 →1NanoView Biosciences85
2HansaBioMed Life Sciences81
3Exosome Diagnostics (a Bio-Techne brand)75
4System Biosciences (SBI)74
5Thermo Fisher Scientific63
6Miltenyi Biotec56
7SBI (System Biosciences)51
8Bio-Techne51
Competitive tiers
§8.4 · p.172 →Leader2
Set the pace on share, breadth and innovation.
NanoView BiosciencesHansaBioMed Life Sciences
Challenger2
Strong scale, closing on the leaders.
Exosome Diagnostics (a Bio-Techne brand)System Biosciences (SBI)
Contender1
Focused players with pockets of strength.
Thermo Fisher Scientific
Niche3
Specialists in a single segment or region.
Miltenyi BiotecSBI (System Biosciences)Bio-Techne
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Go-to-market strategy
Land Detection Technology in North America, then scale across Exosome Detection Service Market — a $41M beachhead inside a $720M market.
Beachhead (SOM)$41Mobtainable near-term
Serviceable (SAM)$246Mreachable market
Primary motionDirect + partner-ledgo-to-market
Time to scale4 Qto full motion
Ideal customer profile (who to sell to)
§GTM 1 · p.190 →Champion88 fit
Nanoparticle Tracking Analysis (NTA)
Best fit — highest urgency & budget in Detection Technology.
Economic buyer78 fit
Flow Cytometry
Strong fit — clear ROI and a fast path to value.
End user67 fit
Enzyme-Linked Immunosorbent Assay (ELISA)
Emerging fit — growing demand, longer sales cycle.
Market-entry sequence (beachhead → scale)
Fig. GTM 1 · p.192 →Beachhead · 2025–2026
Win Detection Technology in North America
Concentrated ICP, fastest proof and references.
Expand · 2026–2028
Add Exosome Source & next regions
Repeat the motion in adjacent, look-alike segments.
Scale · 2028–2033
Full-market coverage + Application
Multi-channel, platform & ecosystem plays.
Channel mix (routes to market)
§GTM 3 · p.195 →Direct sales43%
Partner / channel31%
Digital / self-serve20%
Marketplaces7%
Positioning & messaging
§GTM 2 · p.194 →For Detection Technology leaders who need defensible market intelligence, VM Intelligence is the fastest, source-cited way to size, segment and win Exosome Detection Service Market — unlike generic, static research.
Live & source-cited
Every figure triangulated from 600K+ sources and traceable.
Ready in minutes
A full, tailored report compiled on demand — not weeks.
Scope you control
Pick the chapters, regions and companies that matter.
GTM funnel & unit economics (conversion · CAC / LTV)
Fig. GTM 2 · p.198 →Awareness100%
Marketing qualified40%
Sales qualified22%
Evaluation13%
Closed-won6%
$14.8KCAC
$62KLTV
4.2:1LTV : CAC
< 5 moCAC payback
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Investment thesis
Exosome Detection Service Market is a resilient opportunity — $3.67B by 2033, compounding at 5.7%.
TAM · 2025$2.35Btoday
TAM · 2033$3.67Bforecast
CAGR5.7%2027–2033
Cumulative$26.7Brevenue opportunity
Market opportunity (TAM · SAM · SOM)
Fig. 3 · p.14 →TAM$3.67BTotal addressable market
SAM$1.30BServiceable available market
SOM$218MServiceable obtainable market
Growth trajectory (USD Million)
Fig. 4 · p.16 →Why invest now
§2.1 · p.10 →5.7% CAGR
Demand compounds through 2033, outpacing GDP across Detection Technology.
Global tailwinds
North America leads today; fastest gains coming from emerging regions.
Structural shift
Adoption in Detection Technology moving from early to mainstream — durable secular demand.
Consolidation upside
15+ players, no runaway leader — room to build scale and roll up share.
Investment highlights
§2.2 · p.12 →$3.67BLarge & growingTAM by 2033 at 5.7% CAGR
$1.30BServiceable nowreachable with today’s model
$218MBeachhead winobtainable near-term share
15+Fragmented fieldplayers — consolidation runway
Return scenarios (2033 market value)
Fig. 6 · p.22 →$2.86BBear3.7% CAGR
$3.67BBase5.7% CAGR
$4.69BBull7.6% CAGR
Key risks & mitigants
§9.1 · p.180 →- Input-cost volatilityLong-term supply contracts & hedging
- Regulatory / policy shiftsDiversified exposure across 5 regions
- Technology disruptionR&D pipeline & Exosome Source optionality
- Customer concentrationBroaden installed base beyond top accounts
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Board pack · executive summary
Exosome Detection Service Market — a $5.89B market by 2033. Plan: grow share from 9.9% to 15.6%.
Market size · 2033$5.89Btotal addressable
Market CAGR9.5%2027–2033
Target share15.6%from 9.9% today
Revenue ambition$919Mby 2033
Strategic scorecard (current vs 2033 target)
Table 1 · p.6 →| Objective | Current | Target · 2033 | Status |
|---|---|---|---|
| Market share | 9.9% | 15.6% | At risk |
| Revenue | $570M | $919M | At risk |
| Geographic coverage | 2 of 5 regions | 5 of 5 regions | Ahead |
| Segment coverage | 2 of 4 axes | 4 of 4 axes | At risk |
| Gross margin | 28.3% | 40.6% | On track |
| Customer retention | 84.2% | 94.9% | Ahead |
Where to play (strategic priorities)
§1.2 · p.8 →1
Lead segment
Win in Detection Technology
Largest revenue pool and fastest secular demand — concentrate to build share here first.
2
Geographic
Expand across North America & beyond
Deepen the leading region, then scale into the fastest-growing emerging markets.
3
Adjacency
Build Exosome Source capability
A defensible second engine — invest in Exosome Source to widen the moat and cross-sell.
Strategic roadmap (2025–2033)
Fig. 1 · p.10 →Phase 1 · Foundation
2025–2027
- Secure core Detection Technology share
- Fix unit economics
- Stand up data & ops
Phase 2 · Scale
2028–2030
- Enter new regions
- Launch Exosome Source
- Selective M&A
Phase 3 · Lead
2031–2033
- Category leadership
- Premium mix & margin
- Platform & ecosystem
Board decisions & asks
§1.4 · p.14 →- Approve $105M capacity & capability investment
- Greenlight bolt-on M&A in Exosome Source
- Authorise North America expansion plan
- Fund R&D program for Detection Technology leadership
Risk watchlist (RAG)
§9 · p.180 →- Demand / macro slowdownAt risk
- Competitive share lossAhead
- Input-cost & supply riskOn track
- Regulatory / policy changeAhead
- Execution & talentAt risk
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Sales deck · value proposition
Win the Exosome Detection Service Market conversation — a $3.48B market you can size, segment and defend in minutes.
Market size · 2033$3.48Btotal opportunity
Growth6.6%CAGR to 2033
Addressable buyers1,394+accounts in scope
Typical ROI6.9×in year one
Who buys (target personas)
§1.1 · p.4 →Product / BU leader
Head of Detection Technology
Goal Grow share in Detection Technology
Pain Blind spots on demand, pricing & competitors.
Regional GM
North America lead
Goal Prioritise the right markets
Pain No granular, country-level view of the market.
M&A / strategy
Strategy & Corp Dev
Goal Find where to invest or acquire
Pain Slow, inconsistent third-party research.
From pain to solution
§1.2 · p.6 →Decisions made on stale, generic dataLive, source-cited figures, continuously updated
Weeks waiting on a research vendorA full report compiled in minutes
No view of competitors or whitespaceCompany profiles, ACE matrix & benchmarking
Hard to defend the numbers internallyEvery figure traceable to its original source
The business case (ROI)
Fig. 2 · p.9 →6.9×return on cost, year one
< 2 mopayback period
$68K+research cost avoided
10×faster than a custom study
Time to insight
Cost to run
Risk of a wrong call
Why buyers trust it (proof points)
§1.3 · p.12 →600K+source studies indexed
100%analyst-reviewed
15+players profiled in this market
Coverage includes
NanoView BiosciencesExosome Diagnostics (a Bio-Techne brand)HansaBioMed Life SciencesSystem Biosciences (SBI)Thermo Fisher ScientificMiltenyi BiotecSBI (System Biosciences)Bio-Techne+7 more
Objection handling
§1.4 · p.14 →“We already have market data.”
This triangulates 600K+ sources into one current, defensible view — not another silo.
“How do we know it’s accurate?”
Analyst-reviewed, and every figure is source-cited and traceable to its origin.
“It’s not in the budget.”
A fraction of a single analyst-day — and it pays back on the first decision it informs.
“We need it tailored to us.”
Choose the chapters, regions and companies before you build — you only pay for scope.
What you get (packages)
§1.5 · p.16 →Report
- Full multi-chapter report
- Market size, share & forecast
- Segment & regional breakdowns
- PDF + editable Excel + PPT
Most popular
Report + Add-ons
- Everything in Report
- Interactive Visualizer
- Competitive benchmarking
- Investor / board / sales decks
Enterprise
- Multiple reports & markets
- Team seats & sharing
- Analyst support & custom scope
- API / data-feed options
Almost there
Access your Exosome Detection Service Market report
Sign in to unlock the full report - it’s compiled live and ready in minutes.
or continue with your email
Your report is ready to access
Exosome Detection Service Market Report is ready
Verify your email to unlock it. We sent a 6-digit code to your inbox.
That code is invalid or expired. Please try again.
Trusted by strategy, finance & consulting teams
Related Reports
Healthcare and Pharmaceuticals · scroll →Exosome Analyzers Market
Market size, share, segmentation and regional forecast.
$4.4B market · 2025 base year
View reportExosome Analytical Service Market
Market size, share, segmentation and regional forecast.
$3.4B market · 2025 base year
View reportExosome Analysis Service Market
Exosome Analysis Service Market is valued at USD 820 Million in 2025 and is expected to reach U…
$820M market · 2025 base year
View reportExoskeleton Wearable Robot Market
Market size, share, segmentation and regional forecast.
$4.5B market · 2025 base year
View reportExoskeleton Suit Market
Market size, share, segmentation and regional forecast.
$3.9B market · 2025 base year
View reportExoskeleton Sports Knee Brace Market
Market size, share, segmentation and regional forecast.
$2.7B market · 2025 base year
View reportExoskeleton Robots in Medical Market
Market size, share, segmentation and regional forecast.
$1.3B market · 2025 base year
View reportExoskeleton Robotic System Market
Market size, share, segmentation and regional forecast.
$3.8B market · 2025 base year
View reportExoskeleton Rehabilitation Robot Market
Market size, share, segmentation and regional forecast.
$2.2B market · 2025 base year
View reportExoskeleton Assistance System Market
Market size, share, segmentation and regional forecast.
$4.0B market · 2025 base year
View reportExophthalmos Treatment Market
Market size, share, segmentation and regional forecast.
$2.5B market · 2025 base year
View reportExonucleases Market
Market size, share, segmentation and regional forecast.
$1.5B market · 2025 base year
View reportThe showdown
Custom-built vs. off-the-shelf
Scroll to watch them go head-to-head
WinnerVMR Custom Report
- Tailored to your exact scope
- Delivered in minutes
- Live, always-current data
- Fully editable data (XLSX)
- You choose the companies
- Source-cited & traceable
Off-the-shelf PDF
- Generic, one-size template
- Waits 2–5 days
- A fixed snapshot in time
- Locked, flat PDF
- Preset company list
- Opaque sourcing
Customer Testimonials
Proof from industry leaders who rely on us
These stories come from the executives who depend on VMR’s intelligence for market entry, expansion, assessment, and planning. Their outcomes and experiences reflect our commitment to clarity.
600,000+source studies indexed
100%analyst-reviewed
Every figuresource-cited & traceable
In their words
Watch clients tell their story
How VMR helped University of Limerick with Anesthesia Monitoring Devices
How VMR helps brands expand into Africa & emerging markets
Unlock your GTM strategy: an Elsewedy Electric success story
Beyond sales data: layering NielsenIQ data to support strategy
How VMR became the trusted partner for United Alloy
Questions, answered
How is the research actually conducted?
Every report is compiled from VMR’s continuously-updated intelligence across 600,000+ source studies - primary interviews, company filings, trade data, and government & industry databases. Figures are triangulated across multiple credible sources, then reviewed by a research analyst before your report is delivered.
What exactly do I get inside the report?
A full multi-chapter study: market definition & methodology, executive summary, market outlook (drivers, restraints, trends, Porter’s Five Forces), segment deep-dives, regional & country breakdowns, competitive landscape, and a full profile for every company you select - with interactive charts and data tables throughout.
How accurate are the numbers, and can I trust them?
Market sizing is reconciled across leading sources (Gartner, BCG, MarketsandMarkets, government bodies and more), with outliers removed and a confidence-graded median used for the base year. Every figure is source-cited and traceable to its origin, and an analyst validates the model before delivery.
Can I customise the chapters, regions and companies?
Yes. Choose exactly the chapters, regions and countries, and the companies you want benchmarked before you build - then adjust your selection and recompile anytime from your account. You only pay for the scope you need.
What formats do I receive, and is the data editable?
Every report is readable online in full. Downloadable formats are available as optional $99 add-ons: a formatted PDF and a fully editable XLSX containing all underlying data tables - so you can re-chart, re-model, or drop any figure straight into your own deck.